Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 4.98 · gapped above the open, never looked back. High/low 5.10 at 9:30 am ET, 4.98 at 3:45 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In February 2004, we entered into a license agreement with Bristol-Myers Squibb (BMS) under which we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ ® .”
FILING10-K0001628280-26-007460cik 0001347178
“In April 2012, we entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which we acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize NEREUS TM for all human indications.”
FILING10-K0001628280-26-007460cik 0001347178
“We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.”
FILING10-K0001193125-26-088290cik 0001370053disclosed by ANAB
“At that time, we had certain worldwide exclusive rights relating to Fanapt ® , which we obtained pursuant to a sublicense agreement entered into with Novartis Pharma AG (Novartis) in June 2004.”
FILING10-K0001628280-26-007460cik 0001347178
“We have agreements in place with Patheon Pharmaceuticals Inc. and Patheon Inc. (collectively, Patheon), subsidiaries of Thermo Fisher Scientific, for the manufacture of Fanapt ® and HETLIOZ ® .”
FILING10-K0001628280-26-007460cik 0001347178
“PONVORY ® tablets were approved in the U.S. for the treatment of RMS in adults in March 2021 and commercially launched in the U.S. by Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company in April 2021.”
FILING10-K0001628280-26-007460cik 0001347178
“In December 2023, we purchased the rights to market and sell PONVORY ® in the U.S. and Canadian markets from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company.”
FILING10-K0001628280-26-007460cik 0001347178
“In March 2017, we entered into a license agreement with the University of California San Francisco (UCSF), under which we acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors.”
FILING10-K0001628280-26-007460cik 0001347178
“We paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December 2019 related to manufacturing know-how.”
FILING10-K0001628280-26-007460cik 0001347178
“The FDA has approved Abbreviated New Drug Applications (ANDA) for generic versions of HETLIOZ ® for Teva Pharmaceuticals USA, Inc. (Teva), Apotex Inc. (Apotex) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN).”
FILING10-K0001628280-26-007460cik 0001347178
“The FDA has approved Abbreviated New Drug Applications (ANDA) for generic versions of HETLIOZ ® for Teva Pharmaceuticals USA, Inc. (Teva), Apotex Inc. (Apotex) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN).”
FILING10-K0001628280-26-007460cik 0001347178
“The FDA has approved Abbreviated New Drug Applications (ANDA) for generic versions of HETLIOZ ® for Teva Pharmaceuticals USA, Inc. (Teva), Apotex Inc. (Apotex) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN).”
FILING10-K0001628280-26-007460cik 0001347178
“In 2022, we announced a research and development collaboration agreement with OliPass Corporation (OliPass) to jointly develop a set of ASO molecules based on OliPass' proprietary modified peptide nucleic acids.”
FILING10-K0001628280-26-007460cik 0001347178
Watchlist prices, news filtered to it, and its next report on your desk.
Vanda Pharmaceuticals Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Vanda Pharmaceuticals Inc. has 13 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Vanda Pharmaceuticals Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Vanda Pharmaceuticals Inc.. Customers appear here when Vanda Pharmaceuticals Inc. names them, or when a company names Vanda Pharmaceuticals Inc. as a supplier in its own annual report.
VNDA (Vanda Pharmaceuticals Inc.) has 13 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY −2.03%, in industrials & materials.